Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) shot up 0.7% on Monday . The stock traded as high as $15.78 and last traded at $15.41. Approximately 358,011 shares traded hands during mid-day trading, an increase of 73% from the average daily volume of 206,803 shares. The stock had previously closed at $15.30.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on IMUX shares. D. Boral Capital lowered Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Wolfe Research began coverage on Immunic in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Guggenheim began coverage on shares of Immunic in a research report on Tuesday, March 24th. They set a “buy” rating and a $70.00 price objective on the stock. Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, May 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $47.57.
Check Out Our Latest Stock Report on IMUX
Immunic Stock Up 0.7%
Immunic (NASDAQ:IMUX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.37). Analysts expect that Immunic, Inc. will post -4.57 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Immunic
A number of hedge funds have recently bought and sold shares of IMUX. Jane Street Group LLC increased its position in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after acquiring an additional 152,726 shares during the period. Vanguard Group Inc. boosted its holdings in Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares during the period. GSA Capital Partners LLP acquired a new stake in Immunic in the 3rd quarter worth $170,000. Squarepoint Ops LLC bought a new position in shares of Immunic during the 3rd quarter worth about $239,000. Finally, Two Sigma Investments LP bought a new position in shares of Immunic during the 3rd quarter worth about $52,000. 51.82% of the stock is currently owned by institutional investors.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.
Featured Articles
- Five stocks we like better than Immunic
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
